Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Riku Koivusalo"'
Autor:
Riku Koivusalo, Juha Välimäki
Publikováno v:
Acta Ophthalmologica. 98:305-309
PURPOSE To study the effect of glaucoma drainage implant (GDI) surgery on corneal topography during the first postoperative year. METHODS Twenty-one adult glaucoma patients were implanted with a Molteno3 or a Baerveldt 250 GDI. Corneal topography mea
Autor:
Klaus Elenius, Teemu T. Junttila, Randall S. Johnson, Henrik Söderström, Jukka Westermarck, Tim H. Holmström, Sakari Hietanen, Matti Sankinen, Riku Koivusalo, Anastassios C. Papageorgiou, Antoine Mialon
Publikováno v:
Molecular and Cellular Biology. 25:5040-5051
DNA topoisomerase I (Topo I) is a molecular target for the anticancer agent topotecan in the treatment of small cell lung cancer and ovarian carcinomas. However, the molecular mechanisms by which topotecan treatment inhibits cancer cell proliferation
Publikováno v:
Molecular Pharmacology. 68:372-382
Constant expression of E6 and E7 mRNA by high-risk human papillomaviruses (HPV) abrogates p53 and retinoblastoma protein function, respectively, and is essential for the development of cervical cancer. Despite E6, some chemotherapy drugs can stabiliz
Autor:
Sakari Hietanen, Riku Koivusalo
Publikováno v:
Cancer Biology & Therapy. 3:1177-1183
Metastatic cervical cancer remains a clinical problem. The development of more efficient treatment modalities and the optimal use of chemo- and radiotherapy require better understanding of their impact on regulation of cell survival and apoptosis, bu
Publikováno v:
Cancer research. 66(24)
p53 is degraded in cervical cancer cells by the human papillomavirus E6 and can be stabilized with short interfering RNA (siRNA) molecules targeting E6 mRNA. In this in vitro study, we show that E6 siRNA–induced p53 activation is transient in HeLa
Publikováno v:
Cancer research. 62(24)
Recent clinical trials comparing concurrent chemotherapy and radiation with radiation alone in cervical cancer have shown that chemoradiation reduces the risk of death by 30-50%. Despite the clinical success, treatment responses at the cellular level